Development of dorzolamide hydrochloride in situ gel nanoemulsion for ocular delivery

Drug Development and Industrial Pharmacy

Volumn 36, Issue 11, 2010, Pages 1330-1339

  Ammar, H O ^a   Salama, H A ^a   Ghorab, M ^b   Mahmoud, A A ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Bioavailability; Dorzolamide hydrochloride; In situ gel; Nanoemulsion; Ocular

Indexed keywords

DORZOLAMIDE; POLOXAMER; TRIACETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG MARKETING; DRUG MECHANISM; DRUG RELEASE; DRUG SOLUTION; MALE; NANOEMULSION; NONHUMAN; RABBIT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL AVAILABILITY; DELAYED-ACTION PREPARATIONS; EMULSIONS; EXCIPIENTS; EYE; GELS; MALE; NANOPARTICLES; POLOXAMER; RABBITS; SULFONAMIDES; SURFACE-ACTIVE AGENTS; THIOPHENES; TIME FACTORS;

EID: 77956937545     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639041003801885     Document Type: Article

References (63)

1. Kaur IP, Smitha R, Aggarwal D, Kapil M. (2002). Acetazolamide: Future perspective in topical glaucoma therapeutics. Int J Pharm, 248:1-14.
2. Blomdahl S, Calissendorff BM, Tengrowth B, Wallin O. (1997). Blindness in glaucoma patients. Acta Ophthalmol, 75:589-591
3. Munier A, Gunning T, Kenny D, OKeefe M. (1998). Causes of blindness in the adult population of the Republic of Ireland. Br J Ophthalmol, 82:630-633
4. Hoyng PF, van Beek LM. (2000). Pharmacological therapy for glaucoma: A review. Drugs, 59:411-434
5. Balfour JA, Wilde MI. (1997). Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. Drugs Aging, 10:384-403.
6. Rusk C, Sharpe E, Laurence J, Polis A, Adamsons I. (1998). Comparison of the efficacy and safety of 2% dorzolamide and 0.5% betaxolol in the treatment of elevated intraocular pressure. Dorzolamide Comparison Study Group. Clin Ther, 20:454-466
7. Silver LH. (2000). Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: Results from two multicenter comfort studies. Brinzolamide Comfort Study Group. Surv Ophthalmol, 44(Suppl. 2):S141-5.
8. Afouna MI, Khedr A, Abdel-Naim AB, Al-Marzoqi A. (2010). Influence of various concentrations of terpene-4-ol enhancer and carbopol-934 mucoadhesive upon the in vitro ocular transport and the in vivo intraocular pressure lowering effects of dorzolamide ophthalmic formulations using albino rabbits. J Pharm Sci, 99:119-127
9. Hughes PM, Mitra AK. (1993). Overview of ocular drug delivery and iatrogenic ocular cytopathologies. In: Mitra AK, ed. Ophthalmic drug delivery systems. New York: Marcel Dekker, 1-27.
10. Ma WD, Xu H, Wang C, Nie SF, Pan WS. (2008). Pluronic F127-g-poly(acrylic acid) copolymers as in situ gelling vehicle for ophthalmic drug delivery system. Int J Pharm, 350:247-256
11. Edsman K, Carlfors J, Petersson R. (1998). Rheological evaluation of poloxamer as an in situ gel for ophthalmic use. Eur J Pharm Sci, 6:105-112 (Pubitemid 28164280)
12. Bourlais CL, Acar L, Zia H, Sado PA, Needham T, Leverge R. (1998). Ophthalmic drug delivery systems-recent advances. Prog Retin Eye Res, 17:33-58.
13. Kim EY, Gao ZG, Park JS, Li H, Han K. (2002). rhEGF/HP-beta-CD complex in poloxamer gel for ophthalmic delivery. Int J Pharm, 233:159-167
14. García-Celma MJ. (1997). Solubilization of drugs in microemulsions. In: Solans C, Kunieda H, eds. Industrial applications of microemulsions. New York: Marcel Dekker, 123-145
15. Silva-Cunha A, Fialho SL, Carneiro LB, Oréfice F. (2003). Microemulsões como veículos de drogas para administraç ão ocular tópica. Arq Bras Oftalmol, 66:385-391
16. Vandamme TF. (2002). Microemulsions as ocular drug delivery systems: Recent developments and future challenges. Prog Retin Eye Res, 21:15-34.
17. Azeem A, Ahmad FJ, Khar RK, Talegaonkar S. (2009). Nanocarrier for the transdermal delivery of an antiparkinsonian drug. AAPS PharmSciTech, 10:1093-1103
18. Jain R, Patravale VB. (2009). Development and evaluation of nitrendipine nanoemulsion for intranasal delivery. J Biomed Nanotechnol, 5:62-68
19. Shakeel F, Ramadan W. (2010). Transdermal delivery of anticancer drug caffeine from water-in-oil nanoemulsions. Colloids Surf B Biointerfaces, 75:356-362
20. Ammar HO, Salama HA, Ghorab M, Mahmoud AA. (2009). Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS PharmSciTech, 10:808-819
21. Garti N, Aserin A, Tiunova I, Fanun M. (2000). A DSC study of water behavior in water-in-oil microemulsions stabilized by sucrose esters and butanol. Colloids Surf A Physicochem Eng Asp, 170:1-18.
22. Moreno MA, Ballesteros MP, Frutos P. (2003). Lecithin-based oil-in-water microemulsions for parenteral use: Pseudoternary phase diagrams, characterization and toxicity studies. J Pharm Sci, 92:1428-1437
23. Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M. (2007). Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm, 66:227-243 (Pubitemid 46667230)
24. Pandit NK, Kisaka J. (1996). Loss of gelation ability of Pluronic® F127 in the presence of some salts. Int J Pharm, 145:129-136
25. Bentley MV, Marchetti JM, Ricardo N, Ali-Abi Z, Collett JH. (1999). Influence of lecithin on some physical chemical properties of poloxamer gels: Rheological, microscopic and in vitro permeation studies. Int J Pharm, 193:49-55.
26. Zaki NM, Awad GA, Mortada ND, Abd Elhady SS. (2007). Enhanced bioavailability of metoclopramide HCl by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary transport properties. Eur J Pharm Sci, 32:296-307.
27. Miyazaki S, Suzuki S, Kawasaki N, Endo K, Takahashi A, Attwood D. (2001). In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride. Int J Pharm, 229:29-36.
28. Wu C, Qi H, Chen W, Huang C, Su C, Li W, et al. (2007). Preparation and evaluation of a Carbopol/HPMC-based in situ gelling ophthalmic system for puerarin. Yakugaku Zasshi, 127:183-191 (Pubitemid 46089916)
29. Khan KA, Rhodes CT. (1972). Effect of compaction pressure on the dissolution efficiency of some direct compression systems. Pharm Acta Helv, 47:594-607.
30. Baydoun L, Furrer P, Gurny R, Muller-Goymann CC. (2004). New surface-active polymers for ophthalmic formulations: Evaluation of ocular tolerance. Eur J Pharm Biopharm, 58:169-175
31. Draize JH, Woodard G, Calvey HO. (1944). Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther, 82:377-390
32. Hou MJ, Shah DO. (1987). Effects of the molecular structure of the interface and continuous phase on solubilization of water in water/oil microemulsions. Langmuir, 3:1086-1096
33. Garti N, Aserin A, Ezrahi S, Wachtel E. (1995). Water solubilization and chain length compatibility in nonionic microemulsions. J Colloid Interface Sci, 169:428-436
34. Modi A, Tayade P. (2007). A comparative solubility enhancement profile of valdecoxib with different solubilization approaches. Indian J Pharm Sci, 69:274-278
35. Shiao SY, Chhabra V, Patist A, Free ML, Huibers PDT, Gregory A, et al. (1998). Chain length compatibility effects in mixed surfactant systems for technological applications. Adv Colloid Interface Sci, 74:1-29.
36. Mathis GA. (1999). Clinical ophthalmic pharmacology and therapeutics: Ocular drug delivery. In: Gelatt KN, ed. Veterinary ophthalmology. Florida: Lippincott Williams & Wilkins, 291-297
37. Fialho SL, da Silva-Cunha A. (2004). New vehicle based on a microemulsion for topical ocular administration of dexamethasone. Clin Experiment Ophthalmol, 32:626-632
38. USP30-NF25. (2007). Pharmaceutical dosage forms: Ophthalmic preparations. The United State Pharmacopeia, The National Formulary, USP30-NF 25.
39. Ciba-Geigy. (1977). Wissenschaftliche Tabellen Geigy. 8th ed. Basel: Ciba-Geigy.
40. Keipert S, Siebenbrodt I, Lüders F, Bornschein M. (1989). Mikroemulsionen und ihre. Potenzielle pharmazeutische Nutzung. Pharmazie, 44:433-444
41. Vadnere M, Amidon G, Lindenbaum S, Haslam JE. (1984). Thermodynamic studies on the gel-sol transition of some pluronic polyols. Int J Pharm, 22:207-218
42. Nijenhuis KT. (1997). Thermoreversible networks: Viscoelastic properties and structure of gels. Adv Polym Sci, 130:160-193
43. Zhou Z, Chu B. (1987). Anomalous association behavior of an ethylene oxide/propylene oxide ABA block copolymer in water. Macromolecules, 20:3089-3091
44. Zhou Z, Chu B. (1988). Anomalous micellization behavior and composition heterogeneity of a triblock ABA copolymer of (A) ethylene oxide and (B) propylene oxide in aqueous solution. Macromolecules, 21:2548-2554
45. Glatter O, Scherf O, Schillen K, Brown W. (1994). Characterization of a poly(ethylene oxide)-poly(propylene oxide) triblock copolymer (E027-P039-E027) in aqueous solution. Macromolecules, 27:6046-6054
46. Gupta H, Jain S, Mathur R, Mishra P, Mishra AK, Velpandian T. (2007). Sustained ocular drug delivery from a temperature and pH triggered novel in situ gel system. Drug Deliv, 14:507-715.
47. Koffi AA, Agnely F, Besnard M, Kablan Brou J, Grossiord JL, Ponchel G. (2008). In vitro and in vivo characteristics of a thermogelling and bioadhesive delivery system intended for rectal administration of quinine in children. Eur J Pharm Biopharm, 69(1):167-175
48. Dumortier G, Grossiod JL, Zuber M, Couarraze G, Chaumeil JC. (1991). Rheological study of a thermoreversible morphine gel. Drug Dev Ind Pharm, 17:1255-1265
49. Juhasz J, Lenaerts V, Raymond P, Ong H. (1989). Diffusion of rat atrial natriuretic factor in thermoreversible poloxamer gels. Biomaterials, 10:265-268
50. Wei G, Xu H, Ding PT, Li SM, Zheng JM. (2002). Thermosetting gels with modulated gelation temperature for ophthalmic use: The rheological and gamma scintigraphic studies. J Control Release, 83:65-74.
51. Liu T, Chu B. (2000). Formation of homogeneous gel-like phases by mixed triblock copolymer micelles in aqueous solution: FCC to BCC phase transition. J Appl Cryst, 33:727-730
52. Bohorquez M, Koch C, Trygstad T, Pandit N. (1999). A study of the temperature-dependent micellization of Pluronic F127. J Colloid Interface Sci, 216:34-40.
53. Qi H, Chen W, Huang C, Li L, Chen C, Li W, et al. (2007). Development of a poloxamer analogs/carbopol-based in situ gelling and mucoadhesive ophthalmic delivery system for puerarin. Int J Pharm, 337:178-187
54. Choi HK, Jung JH, Ryu JM, Yoon SJ, Oh YK, Kim CK. (1998). Development of in situ-gelling and mucoadhesive acetaminophen liquid suppository. Int J Pharm, 165:33-44.
55. Hughes WFJ. (1948). The tolerance of rabbit cornea for various chemical substances. Bull Johns Hopkins Hosp, 82:338-349
56. Laillier J, Plazonnet B, Le Douarec JC. (1976). Evaluation of an objective method of studying eye irritation. Proc Eur Soc Toxicol, 17:336-350
57. Conquet P, Durand G, Laillier J, Plazonnet B. (1977). Evaluation of ocular eye irritation in the rabbit: Objective versus subjective assessment. Toxicol Appl Pharmacol, 39:129-139
58. Kwon JW, Han YK, Lee WJ, Cho CS, Paik SJ, Cho DI, et al. (2005). Biocompatibility of poloxamer hydrogel as an injectable intraocular lens: A pilot study. J Cataract Refract Surg, 31: 607-613
59. Tamilvanan S, Benita S. (2004). The potential of lipid emulsion for ocular delivery of lipophilic drugs. Eur J Pharm Biopharm, 58:357-368
60. Roggeband R, York M, Pericoi M, Braun W. (2000). Eye irritation responses in rabbit and man after single applications of equal volumes of undiluted model liquid detergent products. Food Chem Toxicol, 38:727-734
61. Lawrence MJ, Rees GD. (2000). Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev, 45:89-121.
62. Kaur IP, Smitha R. (2002). Penetration enhancers and ocular bioadhesives: Two new avenues for ophthalmic drug delivery. Drug Dev Ind Pharm, 28:353-369
63. Calvo P, Alonso MJ, Vila-Jato J, Robinson JR. (1996). Improved ocular bioavailability of indomethacin by novel ocular drug carriers. J Pharm Pharmacol, 48:1147-1152